IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1310 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (48 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed3401    
    Printed89    
    Emailed0    
    PDF Downloaded261    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2008  |  Volume : 74  |  Issue : 3  |  Page : 265-266

Type 1 lepra reaction presenting as immune reconstitution inflammatory syndrome


Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA

Correspondence Address:
Alwyn Rapose
Division of Infectious Diseases, University of Texas Medical Branch, Rte. 0435, 301 University Blvd., Galveston, TX 77555-0435
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.41380

Rights and Permissions



How to cite this article:
Rapose A. Type 1 lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol 2008;74:265-6

How to cite this URL:
Rapose A. Type 1 lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2019 Aug 19];74:265-6. Available from: http://www.ijdvl.com/text.asp?2008/74/3/265/41380


Sir,

There is an increasing awareness of the immune reconstitution inflammatory syndrome (IRIS) in patients initiating antiretroviral therapy. It is likely that there will be more reports of this phenomenon in patients co-infected with HIV and leprosy, especially from India, where there is a high prevalence of both the diseases and antiretroviral therapy is being made available for free by national organizations.

The article by Kharkar et al. [1] raises a number of interesting considerations:

  1. Both cases presented in the article clearly appear to satisfy the clinical and pathologic criteria for the diagnosis of IRIS. However, early definitions of IRIS by French et al., [2] and subsequent validation studies by Robertson et al. , [3] emphasize the need to demonstrate at least 1 log 10 decrease in plasma HIV viral load. The fact that this test (HIV viral load) is not widely available in many countries emphasizes once again the need to develop diagnostic criteria and algorithms that may be universally applicable in all countries.
  2. It was interesting to note that in Case 1, antiretroviral therapy using nevirapine was initiated at a CD4+ lymphocyte count of 299 cells/mm 3 . Although seen more frequently in females, the use of nevirapine in patients with CD4+ lymphocyte counts more than 250 cells/mm 3 is associated with an increased risk of hepatotoxicity, sometimes fatal. [4],[5] This risk was potentially further increased after initiating rifampicin for treatment of leprosy. Hence, close monitoring and follow-up of this patient was essential.
  3. Patients co-infected with HIV and Mycobacterium leprae do not always develop the lepromatous spectrum of leprosy. Conversely, co-infected patients who have lepromatous leprosy (cell-mediated immunity defect), do not have a more rapid progression to AIDS. These observations suggest that M. leprae and HIV affect different CD4+/CD8+ lymphocytes subpopulations of the cell-mediated immune system. Hence, the immuno-pathogenesis of antiretroviral therapy-induced IRIS in leprosy needs to be investigated further.
  4. Finally, it should be noted that the type1 lepra reaction itself is a form of IRIS known to occur in patients with the tuberculoid spectrum of leprosy when they are initiated on anti-leprosy medications.


 
  References Top

1.Kharkar V, Bhor UH, Mahajan S, Khopkar U. Type I lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol 2007;73:253-6.  Back to cited text no. 1    
2.French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. Aids 2004;18:1615-27.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: Validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46.  Back to cited text no. 3  [PUBMED]  
4.Hahn JA, Maier M, Byakika-Tusiime J, Oyugi JH, Bangsberg DR. Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:83-6.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Maniar JK, Shah SR, Verma R, Kamath R, Gupte P, Maniar A. Nevirapine-induced fulminant hepatitis. J Assoc Physicians India 2006;54:957-8.  Back to cited text no. 5  [PUBMED]  




 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow